

MEETING ABSTRACT

Open Access

Hyperthermic ablation by UltraSound Guided High Intensity Focused Ultrasound (USgHIFU) plus Systemic Chemotherapy (SC) for locally advanced pancreatic cancer: the secret of longer survival

Joan Vidal-Jove*, Eloi Perich, Marta Garcia-Bernal, Manuel Alvarez del Castillo

From 2nd European Symposium on Focused Ultrasound Therapy
Rome, Italy. 10-11 October 2013

We describe results in unresectable pancreatic tumors treated with USgHIFU hyperthermia ablation plus adjuvant chemotherapy.

Materials and methods

Forty three cases of non resectable pancreatic tumors were treated from March 2010 to March 2013, and all of them underwent systemic chemotherapy. Clinical responses (thermal ablation achieved) were measured by image techniques. They were 29 Stage III cases and 14 Stage IV cases. Complications were also analyzed.

Results

Clinical responses (ablation obtained) were 82% in all cases, sustained at 8 weeks of the procedure. We obtained 10 complete responses (25%) at the end of the combined treatment, 9 from stage III patients and 2 from stage IV. Major complications included severe pancreatitis with GI bleeding (1), skin burning grade III that required plastic surgery (2). No deaths were registered. Median Survival was 13 month (6 mo - 2.7 year).

Conclusion

HIFU plus SC is a potentially effective and safe modality for the treatment of unresectable pancreatic cancer.

Published: 10 December 2014

doi:10.1186/2050-5736-2-S1-A6

Cite this article as: Vidal-Jove et al.: Hyperthermic ablation by UltraSound Guided High Intensity Focused Ultrasound (USgHIFU) plus Systemic Chemotherapy (SC) for locally advanced pancreatic cancer: the secret of longer survival. *Journal of Therapeutic Ultrasound* 2014 **2** (Suppl 1):A6.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Hospital University Mutua Terrassa, Barcelona, Spain



© 2014 Vidal-Jove et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.